**Gene expression in castration-resistant prostate cancer (mCRPC) patients**

**Background:** Gene expression profiles of mCRPC patients can be valuable for evaluating the likelihood of response to anti-angiogenic therapy. However, few such profiles are available, and they are often specific to populations with different characteristics.

**Objectives:** To develop a gene expression profile that predicts the likelihood of response to anti-angiogenic therapy in mCRPC patients.

**Methods:** A cohort of mCRPC patients was selected based on their response to anti-angiogenic therapy. Gene expression was assessed using microarray analysis. The resulting signature was tested on an independent cohort of patients.

**Results:** The developed signature showed high predictive accuracy for response to anti-angiogenic therapy in mCRPC patients. The signature was also effective in predicting response in patients with different characteristics, such as primary site and metastatic site.

**Conclusion:** The developed gene expression profile is a valuable tool for predicting the likelihood of response to anti-angiogenic therapy in mCRPC patients. It can be used to improve treatment decisions and patient outcomes.